Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,076,944
  • Shares Outstanding, K 1,587,970
  • Annual Sales, $ 28,216 M
  • Annual Income, $ 5,309 M
  • 36-Month Beta 1.61
  • Price/Sales 5.24
  • Price/Cash Flow 14.15
  • Price/Book 29.18

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.22 +3.63%
on 04/03/18
99.91 -8.50%
on 03/26/18
-6.04 (-6.20%)
since 03/23/18
3-Month
88.22 +3.63%
on 04/03/18
125.86 -27.36%
on 01/26/18
-16.88 (-15.59%)
since 01/25/18
52-Week
64.61 +41.50%
on 05/17/17
125.86 -27.36%
on 01/26/18
+26.32 (+40.43%)
since 04/25/17

Most Recent Stories

More News
What's in the Cards for Inogen (INGN) This Earnings Season?

Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.

COO : 227.60 (+1.96%)
TFX : 264.41 (+0.39%)
ABBV : 91.86 (+0.55%)
INGN : 137.81 (-0.49%)
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

JNJ : 126.75 (+0.44%)
VRTX : 155.14 (-0.34%)
NVS : 76.43 (-0.73%)
ABBV : 91.86 (+0.55%)
BMY : 51.78 (+0.39%)
ALXN : 106.09 (-0.39%)
BIIB : 269.47 (+2.79%)
AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for risankizumab,...

ABBV : 91.86 (+0.55%)
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from the ongoing Phase 2b/3 SELECT-SUNRISE clinical trial, showing that at 12 weeks, all doses of...

ABBV : 91.86 (+0.55%)
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?

Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.

CELG : 89.22 (+0.09%)
ABBV : 91.86 (+0.55%)
PFE : 36.69 (-1.00%)
BMY : 51.78 (+0.39%)
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

ABBV : 91.86 (+0.55%)
RHHBY : 27.8200 (-0.36%)
SNY : 40.11 (+0.91%)
BIIB : 269.47 (+2.79%)
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?

Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.

COO : 227.60 (+1.96%)
ABC : 91.43 (+1.43%)
TFX : 264.41 (+0.39%)
ABBV : 91.86 (+0.55%)
Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?

Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.

COO : 227.60 (+1.96%)
ESRX : 76.53 (+1.38%)
TFX : 264.41 (+0.39%)
ABBV : 91.86 (+0.55%)
What Lies Ahead for Vice ETFs?

Vice ETFs, which aim to profit from companies involved in alcohol, tobacco or gambling, are gathering steam.

WSKY : 33.23 (-0.92%)
ACT : 24.86 (+0.81%)
MGPI : 93.31 (+0.32%)
STZ : 226.88 (+0.29%)
GWPH : 138.79 (+2.12%)
ABBV : 91.86 (+0.55%)
MJ : 28.32 (-0.74%)
Is a Beat in Store for Alexion (ALXN) This Earnings Season?

Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

ABBV : 91.86 (+0.55%)
GILD : 73.24 (+0.72%)
PFE : 36.69 (-1.00%)
ALXN : 106.09 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 94.80
1st Resistance Point 93.08
Last Price 91.86
1st Support Level 90.04
2nd Support Level 88.72

See More

52-Week High 125.86
Fibonacci 61.8% 102.46
Fibonacci 50% 95.24
Last Price 91.86
Fibonacci 38.2% 88.01
52-Week Low 64.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar